NFκB: cell survival or cell death?

Abstract

The present review outlines that the different pathways and components that may influence NFκB, to convert it from an inhibitor of apoptosis into a promoter of apoptosis, are quite versatile. As a consequence inhibition of the NFκB as a global concept to fight cancer should be reconsidered, although of course it seems reasonable for many incidences. Conclusively, cancer therapy can not be generalized but requires individual treatment. (An abstract was missing and has been ‘invented’, please correct if needed; no more than 200 words)